.avif)
Medimmune Email Format
Pharmaceutical Manufacturing
・
10,001+ employees
・
Cambridge, Cambridgeshire, UK
MedImmune is a biopharmaceutical company and the global biologics research and development arm of AstraZeneca, focused on developing innovative therapies for serious diseases.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
lastfirstinitial@medimmune.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1988
Headquarters
Cambridge, Cambridgeshire, UK
Revenue
$10B+
FUNDING Stage
Public
Website
Key Executives
Pascal Soriot (Executive Director and Chief Executive Officer), Aradhana Sarin (Executive Director and Chief Financial Officer), Renee Iacona (Vice President, Oncology Biometrics & Chief Operating Officer, Oncology R&D)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Medimmune?
Medimmune uses the firstinitiallast format on medimmune.com, so Jane Smith would be jsmith@medimmune.com.
What therapeutic areas does Medimmune focus its biologics research on?
Medimmune conducts biologics research and development across respiratory disease, inflammation and autoimmunity, and oncology, with notable pipeline candidates including benralizumab for asthma and durvalumab for multiple cancer types.
Where is the main Medimmune R&D campus located?
The primary Medimmune R&D campus is in Gaithersburg, Maryland, which serves as one of AstraZeneca's six strategic global R&D centers and houses biologics laboratories, pilot-scale manufacturing, and office space.
How can I find and verify a Medimmune contact's email address before reaching out?
Since Medimmune uses the firstinitiallast format at medimmune.com, you can build most addresses directly from a contact's name. A tool like Clay can help you verify those addresses and enrich your prospect list with additional Medimmune contacts.
Which well-known vaccines and biologic medicines were developed by Medimmune?
Medimmune developed Synagis, a biologic used to prevent serious respiratory syncytial virus infections in high-risk infants, and FluMist, the first nasally administered influenza vaccine approved for use in children and adults.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating